Stem-Cell-Derived Islet Therapy for Type 1 Diabetes: What’s Known
Type 1 diabetes is a chronic autoimmune disease in which insulin-producing beta cells in the pancreas are destroyed, leading to insulin deficiency. The 2026 Department of Health Research (DHR) guideline states that management of type 1 diabetes involves insulin replacement therapy along with lifestyle modifications and nutritional support.
Researchers are investigating stem cell therapy as a potential approach for diabetes. One area receiving significant research attention is stem-cell-derived islet therapy, which aims to provide insulin-producing cells to people with type 1 diabetes.
For patients researching stem cell therapy for type 1 diabetes India, it is important to distinguish between emerging clinical research and treatments currently recommended for routine clinical practice.
What Is Stem-Cell-Derived Islet Therapy?
Stem-cell-derived islet therapy involves the use of stem-cell-derived products containing cells intended to perform pancreatic islet functions.
One approach currently being studied is zimislecel, an allogeneic stem-cell-derived islet-cell therapy. In a phase 1–2 clinical study, researchers evaluated whether the treatment could produce islet function in people with type 1 diabetes.
The researchers assessed serum C-peptide following a mixed-meal tolerance test as an indicator of engraftment and islet function.
What Is Stem Cell Therapy for Cerebral Palsy?
Stem-cell-derived islet therapy involves the use of stem-cell-derived products containing cells intended to perform pancreatic islet functions.
One approach currently being studied is zimislecel, an allogeneic stem-cell-derived islet-cell therapy. In a phase 1–2 clinical study, researchers evaluated whether the treatment could produce islet function in people with type 1 diabetes.
The researchers assessed serum C-peptide following a mixed-meal tolerance test as an indicator of engraftment and islet function.
Why Is Islet Cell Therapy Being Studied?
Type 1 diabetes involves the destruction of insulin-producing beta cells. This has led researchers to investigate approaches that could provide replacement insulin-producing cells.
Stem-cell-derived islet therapy is being studied because it may provide a source of cells for transplantation. However, research is still needed to determine how consistently these cells can function and how durable their effects are.
The 2026 DHR guideline identifies stem cell therapy for diabetes as an area requiring evidence-based evaluation and specifically emphasizes the need to assess its effectiveness and safety.
What Do Recent Clinical Trials Show?
A phase 1–2 study of zimislecel was published in the New England Journal of Medicine in 2025.
The study included 14 participants who completed at least 12 months of follow-up. C-peptide was undetectable at baseline in all participants. After treatment, C-peptide was detected in all 14 participants, providing evidence of engraftment and islet function.
Among the 12 participants who received the full dose, all were free from severe hypoglycemic events and had glycated hemoglobin levels below 7% during the study’s specified assessment period. Ten of those 12 participants, or 83%, were insulin-independent at day 365.
These findings provide clinical evidence that the studied stem-cell-derived islet product produced measurable islet function in the participants.
However, the authors described the study as small and short-term and concluded that the findings warrant further clinical investigation.
What Does Insulin Independence Evidence Mean?
Insulin independence evidence refers to participants being able to stop using externally administered insulin for a defined period while meeting the study’s specified criteria.
In the 2025 zimislecel study, 10 of the 12 participants who received the full dose were insulin-independent at day 365.
This result comes from a small phase 1–2 study and should not be interpreted as evidence that stem-cell-derived islet therapy will produce insulin independence in every person with type 1 diabetes.
The study’s authors specifically described the results as supporting further clinical investigation.
What Does the 2026 DHR Guideline Say?
The Department of Health Research (DHR), Government of India, published its Evidence-based Guidelines for the Use of Stem Cell Therapy: Endocrinological Conditions in January 2026. The guideline covers type 1 and type 2 diabetes.
For diabetes mellitus, the guideline states that stem cell therapy is not recommended in routine clinical practice for either type 1 or type 2 diabetes.
The recommendation is conditional, with very low certainty of evidence. The guideline states that stem cell therapy may be used only in the context of rigorously conducted randomized controlled trials.
For type 1 diabetes specifically, the guideline reports very low-certainty evidence of a trivial improvement in insulin independence and quality of life.
This guidance is particularly relevant for patients considering stem cell therapy for type 1 diabetes India, because it reflects the current evidence assessment by India’s Department of Health Research.
What Are Diabetes Stem Cell Trials Studying?
Diabetes stem cell trials are evaluating whether stem cell or stem-cell-derived products can provide meaningful benefits for people with diabetes.
The DHR guideline explains that its evidence assessment involved systematic reviews and meta-analyses of randomized controlled trials. The guideline development process included evidence synthesis, assessment of certainty using the GRADE approach, and formulation of recommendations through an Evidence to Decision framework.
The 2025 zimislecel study represents another important step in clinical research, with investigators evaluating engraftment, islet function, glucose control, insulin independence, and safety.
What Should Patients Know Before Considering Treatment?
Patients researching stem cell therapy for type 1 diabetes India should understand the specific treatment being proposed and the evidence supporting it.
Important questions include:
- What type of cells are being used?
- Is the treatment stem-cell-derived islet therapy?
- Is the treatment part of a registered clinical trial?
- What clinical evidence supports the specific treatment?
- What follow-up is required?
- What are the potential risks?
- How will insulin requirements and glucose control be monitored?
Patients should also distinguish between a treatment being studied in a clinical trial and a treatment recommended for routine clinical practice.
How MedTravellers Supports Stem Cell Therapy Enquiries
MedTravellers focuses on stem cell therapy and regenerative medicine, supporting patients exploring stem cell treatment options.
For patients interested in emerging areas such as stem-cell-derived islet therapy, MedTravellers can help coordinate the consultation and treatment-planning process.
The suitability of any treatment should be determined by qualified medical specialists based on the individual patient’s condition and the available clinical evidence.
What Does the Current Evidence Tell Us?
The current evidence shows that stem-cell-derived islet therapy has reached human clinical research, with measurable islet function and insulin independence reported in participants in an early-phase clinical study.
At the same time, the study was small and short-term, and its authors stated that further clinical investigation is warranted.
The 2026 DHR guideline continues to recommend against routine clinical use of stem cell therapy for diabetes and assigns very low certainty to the available evidence.
Therefore, stem-cell-derived islet therapy should currently be understood as an emerging clinical research approach, rather than an established routine treatment for type 1 diabetes.
In Conclusion
Stem cell therapy for type 1 diabetes India is an evolving area of regenerative medicine research. Stem-cell-derived islet cell therapy has produced measurable islet function in clinical research, and insulin independence was reported in 10 of 12 full-dose participants at day 365 in a 2025 phase 1-2 study.
However, the evidence remains limited by the small size and short duration of the study.
The 2026 DHR guideline does not recommend stem cell therapy for routine clinical treatment of diabetes. It gives a conditional recommendation with very low certainty of evidence and states that such therapy may be used only within rigorously conducted randomized controlled trials.
For patients considering this approach, understanding the specific cell therapy, clinical-trial status, available evidence, and potential risks is essential before making a treatment decision.
Disclaimer: This article is for educational purposes only and is not medical advice. Stem-cell-derived islet therapy for type 1 diabetes remains an evolving area of clinical research. Patients should consult qualified medical specialists before making treatment decisions.